Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
News|Articles|June 27, 2017
PTSM: Pharmaceutical Technology Sourcing and Management
- PTSM: Pharmaceutical Technology Sourcing and Management-07-05-2017
- Volume 12
- Issue 7
Itzhak Krinsky Joins Halo Pharma Board of Directors
Author(s)Pharmaceutical Technology Editors
Krinsky joined the board of directors at Halo after working for Teva Pharmaceuticals for 12 years.
Advertisement
On June 27, 2017, Halo Pharma announced the appointment of Itzhak Krinsky, PhD, to its board of directors. Krinsky has experience in the pharmaceutical industry, investment banking, and an academic career in finance and business economics. Prior to joining Halo, Krinsky worked for Teva Pharmaceuticals for 12 years. He retired from Teva earlier in 2017. During his tenure at Teva, Krinsky served as executive vice-president of Corporate Business Development, a member of the Teva executive committee, chairman of Teva Japan, chairman of Teva South Korea, and head of Business Development Asia Pacific.
Prior to joining Teva, he held various senior positions in investment banks in New York City including with Bankers Trust, Deutsche Bank, and the Silverfern Group, Inc. Krinsky also served as a professor of Finance and Business Economics at the Michael G. DeGroote School of Business, McMaster University, Ontario, Canada. He has published more than 80 articles in peer-reviewed academic journals.
Source: Halo Pharma
Articles in this issue
over 9 years ago
Overcoming Concerns to Adopting Continuous Processesover 9 years ago
The Search for Efficient Synthesis of Complex Cannabinoidsover 9 years ago
BASF Ups Ibuprofen Capacities in Germany and North Americaover 9 years ago
Survey Reveals that Blockchain will be Adopted Within Five Yearsover 9 years ago
Agilent Adds Products to InfinityLab LC SeriesAdvertisement
Related to this article
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
2
Can Continuous Tableting End Scale-Up for Complex Oral Drugs?
3
Manufacturing Intelligence: Organoids, Organ-on-a-Chip, and the Trust Gap
4
CPHI Milan: Packaging and Delivery Decisions Must Reflect Real-World Care
5